Alexza Pharmaceuticals (OTCMKTS: ALXA) and Endo International (NASDAQ:ENDP) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.
This is a breakdown of recent ratings and recommmendations for Alexza Pharmaceuticals and Endo International, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Endo International has a consensus target price of $11.50, indicating a potential upside of 40.76%.
Institutional and Insider Ownership
93.1% of Endo International shares are owned by institutional investors. 0.5% of Endo International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Alexza Pharmaceuticals and Endo International’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Endo International||$4.01 billion||0.45||-$3.35 billion||($19.28)||-0.42|
Alexza Pharmaceuticals has higher earnings, but lower revenue than Endo International. Endo International is trading at a lower price-to-earnings ratio than Alexza Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Alexza Pharmaceuticals and Endo International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Endo International beats Alexza Pharmaceuticals on 7 of the 8 factors compared between the two stocks.
About Alexza Pharmaceuticals
Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company’s product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company’s subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.
Receive News & Ratings for Alexza Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexza Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.